7 documents found, page 1 of 1
Predictors of Secukinumab Treatment Response and Continuation in Axial Spondylo...
Pons, Marion; Georgiadis, Stylianos; Hetland, Merete Lund; Ahmadzay, Zohra Faizy; Rasmussen, Simon; Christiansen, Sara N.; Di Giuseppe, DanielaPublisher Copyright: © 2025 The Journal of Rheumatology.; Objective. In patients with axial spondyloarthritis (axSpA) initiating secukinumab (SEC), we aimed to identify baseline (treatment start) predictors of achieving low disease activity (LDA) after 6 months, as measured by the Axial Spondyloarthritis Disease Activity Score using C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity...
Interchangeability of patient pain, fatigue and global scores in patients with ...
Georgiadis, Stylianos; Di Giuseppe, Daniela; Scherer, Almut; Hetland, Merete Lund; Jones, Gareth; Glintborg, Bente; Loft, Anne Gitte; Wallman, Johan KFunding Information: Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. Open access funding provided by Copenhagen University. This work was supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript. Funding Information: The EuroSpA collaboration h...
Disparities in the organisation of national healthcare systems for treatment of...
Michelsen, Brigitte; Østergaard, Mikkel; Nissen, Michael John; Ciurea, Adrian; Möller, Burkhard; Midtbøll Ørnbjerg, Lykke; Horák, PavelBackground: Studies on national policies for biologics are warranted. Objectives: To map and compare national healthcare set-ups for prescription, start, switch, tapering, and discontinuation of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis and axial spondyloarthritis across Europe, and assess the healthcare set-ups in relation to countries' soci...
Impact of patient characteristics on ASDAS disease activity state cut-offs in a...
Ørnbjerg, Lykke M.; Georgiadis, Stylianos; Kvien, Tore K.; Michelsen, Brigitte; Rasmussen, Simon; Pavelka, Karel; Zavada, Jakub; Loft, Anne GitteObjectives: To re-evaluate cut-offs for disease activity states according to the Axial Spondyloarthritis Disease Activity Score (ASDAS), and study the impact of sex, age, calendar time, disease and symptom duration on ASDAS and ASDAS cut-offs in a large contemporary cohort. Methods: Data from 2939 patients with axial spondyloarthritis (axSpA) starting their first tumour necrosis factor inhibitor in nine Europea...
Effectiveness and treatment retention of TNF inhibitors when used as monotherap...
Lindström, Ulf; Di Giuseppe, Daniela; Delcoigne, Bénédicte; Glintborg, Bente; Möller, Burkhard; Ciurea, Adrian; Pombo-Suarez, ManuelBackground: Comedication with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) during treatment with tumour necrosis factor inhibitors (TNFi) is extensively used in psoriatic arthritis (PsA), although the additive benefit remains unclear. We aimed to compare treatment outcomes in patients with PsA treated with TNFi and csDMARD comedication versus TNFi monotherapy. Methods: Patients with P...
Impact of discordance between patient’s and evaluator’s global assessment on tr...
Michelsen, Brigitte; Ørnbjerg, Lykke Midtbøll; Kvien, Tore K.; Pavelka, Karel; Nissen, Michael J.; Nordström, Dan; Santos, Maria; Koca, Suleyman SerdarObjectives: To assess the impact of 'patient's minus evaluator's global assessment of disease activity' (ΔPEG) at treatment initiation on retention and remission rates of TNF inhibitors (TNFi) in psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients across Europe. Methods: Real-life data from PsA and axSpA patients starting their first TNFi from 11 countries in the European Spondyloarthritis Re...
Drug retention, inactive disease and response rates in 1860 patients with axial...
Michelsen, Brigitte; Lindström, Ulf; Codreanu, Catalin; Ciurea, Adrian; Zavada, Jakub; Loft, Anne Gitte; Pombo-Suarez, Manuel; Onen, FatosObjectives: To explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries. Methods: Real-life data from 13 European registries participating in the European Spondyloarthritis R...